Biosensors Designed for the Detection of Breast Cancer Biomarkers by Different Electrochemical Methods

Year 2022, Volume: 1 Issue: 1, 55 - 66, 31.12.2022

Dilek Kazıcı , Ebru Kuyumcu Savan

Abstract

Today, breast cancer is one of the leading causes of cancer deaths, especially in women, as it is a life-threatening type of cancer that is most frequently diagnosed in women worldwide, rarely seen in men. Most deaths from breast cancer are not caused by the tumor itself, but by metastasis to other organs in the body. Therefore, as in all cancer types, early diagnosis of breast cancer can reduce the incidence of metastatic disease and prolong disease-free and survival time. Breast ultrasonography, mammography, breast MRI, positron emission tomography and fine needle biopsy techniques are the most commonly used and the most effective techniques in the diagnosis of breast cancer. However, these methods are limited because they are costly to set up, some methods are painful for the patient, and are not suitable for all ages. Recently, electrochemical methods have become very common because they are fast, sensitive, selective, low-cost, easily prepared and interpreted devices. Accordingly, biosensors are preferred more and more day by day. In this review, it is aimed to summarize the biosensor studies designed for the detection of biomarkers used in the early-stage diagnosis of breast cancer.

Keywords

Breast cancer, biosensor, Electrochemical Determination

References

• [1] Fentiman IS, Fourquet A, Hortobagyi GN. Male breast cancer. The Lancet. 2006; 367(9510): 595–604.
• [2] Sharma GN, Dave R, Sanadya J, Sharma P, et al. Various types and management of breast cancer: an overview. Journal of Advanced Pharmaceutical Technology & Research. 2010; 1(2): 109-126
• [3] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA: A Cancer Journal for Clinicians. 2016; 66(1): 7–30.
• [4] Pepe MS, Etzioni R, Feng Z, Potter JD, et al. Phases of biomarker development for early detection of cancer. JNCI Journal of the National Cancer Institute. 2001; 93(14): 1054–1061.
• [5] Selvolini G, Marrazza G. MIP-based sensors: promising new tools for cancer biomarker determination. Sensors. 2017; 17(4): 718.
• [6] Karellas A, Vedantham S. Breast cancer imaging: a perspective for the next decade. Medical Physics. 2008; 35(11): 4878–4897.
• [7] Mittal S, Kaur H, Gautam N, Mantha AK. Biosensors for breast cancer diagnosis: a review of bioreceptors, biotransducers and signal amplification strategies. Biosensors and Bioelectronics. 2017; 88: 217–231.
• [8] Akbari Nakhjavani S, Afsharan H, Khalilzadeh B, Ghahremani MH, et al. Gold and silver bio/nano-hybrids-based electrochemical immunosensor for ultrasensitive detection of carcinoembryonic antigen. Biosensors and Bioelectronics. 2019; 141: 111439.
• [9] Raamanathan A, Simmons GW, Christodoulides N, Floriano PN, et al. Programmable bio-nano-chip systems for serum CA125 quantification: toward ovarian cancer diagnostics at the point-of-care. Cancer Prevention Research. 2012; 5(5): 706–716.
• [10] Lin C-H, Lin J-H, Chen C-F, Ito Y, et al. Conducting polymer-based sensors for food and drug analysis. Journal of Food and Drug Analysis. 2021; 29(4): 544–558.
• [11] Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994; 266(5182): 66–71.
• [12] Stratton MR, Rahman N. The emerging landscape of breast cancer susceptibility. Nature Genetics. 2008; 40(1): 17–22.
• [13] Oshi M, Murthy V, Takahashi H, Huyser M, et al. Urine as a source of liquid biopsy for cancer. Cancers. 2021; 13(11): 2652.
• [14] Bertoli G, Cava C, Castiglioni I. MicroRNAs: new biomarkers for diagnosis, prognosis, therapy prediction and therapeutic tools for breast cancer. Theranostics. 2015; 5(10): 1122–1143.
• [15] Xu S, Chang Y, Wu Z, Li Y, et al. One DNA circle capture probe with multiple target recognition domains for simultaneous electrochemical detection of miRNA-21 and miRNA-155. Biosensors and Bioelectronics. 2020; 149: 111848.
• [16] Streckfus C, Bigler L, Tucci M, Thigpen JT. A preliminary study of CA15-3, c-erbB-2, epidermal growth factor receptor, cathepsin-D, and p53 in saliva among women with breast carcinoma. Cancer Investigation. 2000; 18(2): 101–109.
• [17] Ludovini V, Gori S, Colozza M, Pistola L, et al. Evaluation of serum HER2 extracellular domain in early breast cancer patients: correlation with clinicopathological parameters and survival. Annals of Oncology. 2008; 19(5): 883–890.
• [18] Streckfus CF, Arreola D, Edwards C, Bigler L. Salivary protein profiles among HER2/neu-Receptor-positive and -negative breast cancer patients: support for using salivary protein profiles for modeling breast cancer progression. Journal of Oncology. 2012; 2012: 1–9.
• [19] Laidi F, Bouziane A, Errachid A, Zaoui F. Usefulness of salivary and serum auto-antibodies against tumor biomarkers HER2 and MUC1 in breast cancer screening. Asian Pacific Journal of Cancer Prevention. 2016; 17(1): 335–339.
• [20] Hudis CA. Trastuzumab — Mechanism of action and use in clinical practice. New England Journal of Medicine. 2007; 357(1): 39–51.
• [21] Sonnenblick A, Brohée S, Fumagalli D, Rothé F, et al. Integrative proteomic and gene expression analysis identify potential biomarkers for adjuvant trastuzumab resistance: analysis from the fin-her phase III randomized trial. Oncotarget. 2015; 6(30): 30306–30316.
• [22] Gam L-H. Breast cancer and protein biomarkers. World Journal of Experimental Medicine. 2012; 2(5): 86-91.
• [23] Abrao Nemeir I, Saab J, Hleihel W, Errachid A, et al. The advent of salivary breast cancer biomarker detection using affinity sensors. Sensors. 2019; 19(10): 2373.
• [24] Johnson CH, Gonzalez FJ. Challenges and opportunities of metabolomics. Journal of Cellular Physiology. 2012; 227(8): 2975–2981.
• [25] Yang L, Wang Y, Cai H, Wang S, et al. Application of metabolomics in the diagnosis of breast cancer: a systematic review. Journal of Cancer. 2020; 11(9): 2540–2551.
• [26] Silva C, Perestrelo R, Silva P, Tomás H, et al. Breast cancer metabolomics: from analytical platforms to multivariate data analysis. A Review. Metabolites. 2019; 9(5): 102.
• [27] Labib M, Sargent EH, Kelley SO. Electrochemical methods for the analysis of clinically relevant biomolecules. Chemical Reviews. 2016; 116(16): 9001–9090.
• [28] Topkaya SN, Azimzadeh M, Ozsoz M. Electrochemical biosensors for cancer biomarkers detection: recent advances and challenges. Electroanalysis. 2016; 28(7): 1402–1419.
• [29] Cui F, Zhou Z, Zhou HS. Review—measurement and analysis of cancer biomarkers based on electrochemical biosensors. Journal of The Electrochemical Society. 2020; 167(3): 037525.
• [30] Wang G, Han R, Su X, Li Y, et al. Zwitterionic peptide anchored to conducting polymer PEDOT for the development of antifouling and ultrasensitive electrochemical DNA sensor. Biosensors and Bioelectronics. 2017; 92: 396–401.
• [31] Wang W, Fan X, Xu S, Davis JJ, et al. Low fouling label-free DNA sensor based on polyethylene glycols decorated with gold nanoparticles for the detection of breast cancer biomarkers. Biosensors and Bioelectronics. 2015; 71: 51–56.
• [32] Torrente-Rodríguez RM, Ruiz-Valdepeñas Montiel V, Campuzano S, Farchado-Dinia M, et al. Fast electrochemical miRNAs determination in cancer cells and tumor tissues with antibody-functionalized magnetic microcarriers. ACS Sensors. 2016; 1(7): 896–903.
• [33] Wu D, Lu H, Wang J, Wu L, et al. Amplified electrochemical detection of circular RNA in breast cancer patients using ferrocene-capped gold nanoparticle/streptavidin conjugates. Microchemical Journal. 2021; 164: 106066.
• [34] Congur G, Erdem A. PAMAM dendrimer modified screen printed electrodes for impedimetric detection of miRNA-34a. Microchemical Journal. 2019; 148: 748–758.
• [35] Xu S, Chang Y, Wu Z, Li Y, et al. One DNA circle capture probe with multiple target recognition domains for simultaneous electrochemical detection of miRNA-21 and miRNA-155. Biosensors and Bioelectronics. 2020; 149: 111848.
• [36] Pimalai D, Putnin T, Waiwinya W, Chotsuwan C, et al. Development of electrochemical biosensors for simultaneous multiplex detection of microRNA for breast cancer screening. Microchimica Acta 2021; 188(10): 329.
• [37] Vasudev A, Kaushik A, Bhansali S. Electrochemical immunosensor for label free epidermal growth factor receptor (EGFR) detection. Biosensors and Bioelectronics. 2013; 39(1): 300–305.
• [38] Omidfar K, Darzianiazizi M, Ahmadi A, Daneshpour M, et al. A high sensitive electrochemical nanoimmunosensor based on Fe3O4/TMC/Au nanocomposite and PT-modified electrode for the detection of cancer biomarker epidermal growth factor receptor. Sensors and Actuators B: Chemical. 2015; 220: 1311–1319.
• [39] Li R, Huang H, Huang L, Lin Z, et al. Electrochemical biosensor for epidermal growth factor receptor detection with peptide ligand. Electrochimica Acta. 2013; 109: 233–237.
• [40] Hartati YW, Letelay LK, Gaffar S, Wyantuti S, et al. Cerium oxide-monoclonal antibody bioconjugate for electrochemical immunosensing of HER2 as a breast cancer biomarker. Sensing and Bio-Sensing Research. 2020; 27: 100316.
• [41] Yola ML. Sensitive sandwich-type voltammetric immunosensor for breast cancer biomarker HER2 detection based on gold nanoparticles decorated Cu-MOF and Cu2ZnSnS4 NPs/Pt/g-C3N4 composite. Microchimica Acta. 2021; 188(3): 78.
• [42] Shen C, Zeng K, Luo J, Li X, et al. Self-assembled DNA generated electric current biosensor for HER2 analysis. Analytical Chemistry. 2017; 89(19): 10264–10269.
• [43] Ferreira DC, Batistuti MR, Bachour B, Mulato M. Aptasensor based on screen-printed electrode for breast cancer detection in undiluted human serum. Bioelectrochemistry. 2021; 137: 107586.
• [44] Ge S, Jiao X, Chen D. Ultrasensitive electrochemical immunosensor for CA 15-3 using thionine-nanoporous gold–graphene as a platform and horseradish peroxidase-encapsulated liposomes as signal amplification. Analytica Chimica Acta. 2012; 137: 4440.
• [45] Rebelo TSCR, Ribeiro JA, Sales MGF, Pereira CM. Electrochemical immunosensor for detection of CA 15-3 biomarker in point-of-care. Sensing and Bio-Sensing Research. 2021; 33: 100445.
• [46] Farzin L, Sadjadi S, Shamsipur M, Sheibani S, et al. Employing AgNPs doped amidoxime-modified polyacrylonitrile (PAN-oxime) nanofibers for target induced strand displacement-based electrochemical aptasensing of CA125 in ovarian cancer patients. Materials Science and Engineering: C. 2019; 97: 679–687.
• [47] Zhao L, Ma Z. Facile synthesis of polyaniline-polythionine redox hydrogel: conductive, antifouling and enzyme-linked material for ultrasensitive label-free amperometric immunosensor toward carcinoma antigen-125. Analytica Chimica Acta. 2018; 997: 60–66.
• [48] Cui Z, Wu D, Zhang Y, Ma H, et al. Ultrasensitive electrochemical immunosensors for multiplexed determination using mesoporous platinum nanoparticles as nonenzymatic labels. Analytica Chimica Acta. 2014; 807: 44–50.